CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Aung Naing, Fiona C. Thistlethwaite, Alexander I. Spira, Javier Garcia-Corbacho, Manreet Randhawa, Ferry Eskens, Bert O'Neil, Javier Lavernia, Nataliya Volodymyrivna Uboha, Omid Hamid, Anthony B. El-Khoueiry, Beverly A. Benson, William Garner, Vanessa Jessica Huels, Hendrik-Tobias Arkenau, Patricia LoRusso
Institutions: The University of Texas MD Anderson Cancer Center, University of Manchester, The Christie NHS Foundation Trust, Virginia Cancer Specialists, Hospital Clínic de Barcelona, Beatson West of Scotland Cancer Centre, Erasmus MC, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Fundación Instituto Valenciano de Oncología, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Angeles Clinic and Research Institute, USC Norris Comprehensive Cancer Center, CytomX Therapeutics (United States), Sarah Cannon Research Institute, Yale Cancer Center, Yale University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947338041